Company intelligence / Profile preview

Alimera Sciences

Alpharetta, Georgia, United Statesalimerasciences.com ↗

Ownership: Public · ALIM
Employees: ~334
Development stage: Commercial

Overview

Alimera Sciences has two main commercial products—ILUVIEN and YUTIQ—both are fluocinolone acetonide intravitreal implants. ILUVIEN is approved in the US and Europe for DME and NIU; YUTIQ is being evaluated in Phase IV studies for chronic NIU. The Synchronicity study on YUTIQ recently completed enrollment with results pending. Both products provide long-term control of retinal inflammation with a single injection lasting up to three years[4][7][10].

Therapeutic areas: Ophthalmology
Modalities: Sustained-release corticosteroid implants (fluocinolone acetonide intravitreal implants)
Industry: Biotech

Drug pipeline

1 asset

Medidur FA

Commercial

Indications: Diabetic macular edema

Partnerships

EyePoint Pharmaceuticals US Inc. – collaboration on development/manufacture/sale of YUTIQOcumension Hong Kong Limited – licensing agreement for China & Greater Western Pacific region distribution/commercializationDistributor partners across Europe and Middle East including France, Spain, Italy etc.[4][8]

Financials

Market cap: $301.3M
Total revenue: $27M
Enterprise value: $360.4M

Beyond the preview

Go deeper on Alimera Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alimera Sciences.

Explore the full profile